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Abstract: Protein C is one of the major inhibitors of the coagulation system that downregulate 
thrombin generation. Severe congenital protein C deficiency leads to a hypercoagulability state 
that usually presents at birth with purpura fulminans and/or severe venous and arterial thrombosis. 
Recurrent thrombotic events are commonly seen. From the 1990’s, several virus-inactivated 
human protein C concentrates have been developed. These concentrates currently constitute the 
therapy of choice for the treatment and prevention of clinical manifestations of severe congenital 
protein C deficiency. This review summarizes the available information on the use of human 
protein C concentrates in patients with severe congenital protein C deficiency.
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Introduction
Protein C (PC) is a vitamin K-dependent coagulation inhibitor produced by hepatocytes. 
Plasma PC circulates as a 62-kDa-precursor serine protease that is activated by thrombin 
bound to a specific membrane protein, thrombomodulin. Together with its cofactor, pro-
tein S, activated PC specifically inhibits factor (F) Va and FVIIIa in a calcium and phos-
pholipid-dependent manner, which in turn downregulates thrombin generation. Similar to 
all other vitamin K-dependent coagulation proteins, plasma concentration of circulating 
PC is significantly decreased at birth and during childhood at approximately 50% and 
20% of adult values, respectively. This age-dependent decreased plasma concentration 
of PC is physiological and does not increase the thrombotic risk during childhood.1
Congenital PC deficiency is an autosomal dominant inherited disorder caused by 
mutations of the PC gene (PROC, OMIM #176860) located on chromosome 2q13–14. 
Thus far, 151 different mutations have been described.2 Reported incidence of het-
erozygous PC deficiency varies between 1 in 200 to 1 in 500 healthy individuals. 
The incidence of homozygous PC deficiency is estimated at 1 in 500 000–750 000 of 
newborns, with an equal distribution between males and females.3
Congenital PC deficiency is associated with an increased risk of thromboembolic 
events. While heterozygous PC deficiency in adult patients is associated with a   
10-fold increased risk of developing thromboembolic events compared to the general 
population, homozygous or double heterozygous PC deficiency represents a severe 
thromboembolic disorder. This usually manifests within hours of birth with life-threat-
ening purpura fulminans (PF) and large-vessel thrombosis requiring urgent therapy 
including PC substitution.4
Until the end of the 1980’s, no human PC concentrates were available. Patients 
with severe PC deficiency were treated with infusions of fresh frozen plasma (FFP) or Biologics: Targets & Therapy 2010:4 52
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cryoprecipitate.5–12 Many of these patients died.6,13 Follow-
ing the introduction of commercially available human PC 
concentrates, several patients have been successfully treated 
and their cases are reported in the literature.14
This review will summarize the available information on 
the use of human PC concentrates to treat severe congenital 
PC deficiency.
Severe congenital protein C 
deficiency
Clinical presentation
While intrauterine and prenatal presentation (including arterial 
ischemic stroke and cerebral hemorrhage, thrombosis of the 
vitreal veins, and retinal arterial thrombosis and hemorrhage) 
has been reported, severe congenital PC deficiency usually 
presents immediately after birth with life-threatening PF and/or 
disseminated intravascular coagulation (DIC).3,5–9,12 Purpura ful-
minans is an acute, progressive hemorrhagic necrosis of the skin 
caused by dermal vascular thrombosis. Lesions present initially 
as small ecchymoses that rapidly become purplish black with 
bullae, and then become necrotic and gangrenous.15–16 Purpura 
fulminans may develop on the extremities, the buttocks, abdo-
men, scrotum, and scalp as well as at pressure points, previous 
punctures locations, and at previously affected sites.4 Following 
the neonatal period, severe PC deficiency may cause further 
episodes of PF triggered by infection or trauma and recurrent 
venous thrombotic events including deep vein thrombosis 
(DVT) and pulmonary embolism (PE).5,13
In patients with homozygous PC deficiency but small 
detectable levels of PC, delayed clinical presentation includ-
ing spontaneous large vessel thrombosis and skin necrosis 
following initiation of oral anticoagulation (OAC) therapy 
with a vitamin K antagonist is usually observed.3,17–21
Overview of treatment options
Treatment options for severe congenital PC deficiency include 
the substitution of PC or liver transplantation. In the early 
1980’s, PC was replaced by the administration of FFP and/or 
cryoprecipitate.5–9 FFP consists of plasma separated from 
red cells and platelets by centrifugation of whole blood and 
frozen to –18°C within 6 hours of collection. One milliliter 
of FFP contains approximately one international unit of each 
of the coagulation factors and inhibitors. Cryoprecipitate is 
the precipitated plasma protein resulting from FFP thawed at 
4°C, re-suspended in a minimal volume of residual supernatant 
plasma and subsequently refrozen at –18°C or lower. One bag 
of cryoprecipitate contains approximately 100 U of factor VIII, 
880 U of von Willebrand factor, 250 mg of fibrinogen, and 50 
U of factor XIII. Both concentrates require frequent plasma 
infusions once to twice daily to achieve significant improve-
ment of symptoms, possibly leading to volume overload.12–14 As 
well, both plasma products are associated with severe adverse 
effects.5,6,9,13,22 Apart from the risk of infection, undesirable 
effects of FFP include allergic reactions, alloimmunization 
from contaminant red cells, and on rare occasions, pulmonary 
edema.12,23–26 A major side effect of cryoprecipitate is passive 
transfer of isoagglutinins from the ABO blood group system 
due to the presence of plasma immunoglobulins.
Factor IX concentrate and PC-rich prothrombin-complex 
concentrate (PCC) have been successfully used in patients 
with severe congenital PC deficiency.10–12 The concentration 
of PC in PCC showed an up to 10-fold variation in several 
brands, leading to a rise in plasma level of PC above 100 
IU/dL with an approximately 7.4-hour half-life.
Following the development of human PC concentrates 
based on knowledge gained from the production of PCC in 
the 1970’s, several virus-inactivated PC concentrates were 
developed in the 1990’s. These currently constitute the treat-
ment of choice for severe congenital PC deficiency. While 
a recombinant-activated PC concentrate (drotrecogin alfa, 
Xigris®) has been successfully administered on different 
occasions to treat episodes of PF in patients with severe con-
genital PC deficiency, the concern about an increased risk of 
major bleeding episodes in children may limit the use of this 
concentrate, at least in the pediatric population.27–31
A curative therapy for severe congenital PC deficiency is 
liver transplantation. Four patients who have undergone suc-
cessful liver transplants have been reported so far. One child 
at 20 months and another at 6 months of age received elective 
living donor liver transplantation.32–33 Angelis et al reported 
an additional girl, who received auxiliary liver and renal 
transplantation due to renal insufficiency following neonatal 
bilateral renal vein thrombosis.34 The fourth successful liver 
transplant was reported in a 5-year-old boy who had previ-
ously been treated with long-term PC replacement therapy.35 
In all patients, PC activity was fully reconstituted.
Human protein C concentrates
Development of human protein C 
concentrates
The first production of human PC concentrates was based 
on the expertise gained from the production of PCC of 
Immuno AG in Vienna, Austria in the 1970’s. The human 
PC concentrate, Ceprotin®, was developed in 1990 and 
first put on the market by Baxter Healthcare Corporation 
(Deerfield, IL, USA) in 1991. Ceprotin® was licensed in Biologics: Targets & Therapy 2010:4 53
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Europe by the European Medicines Evaluation Agency in 
2001 for patients with congenital PC deficiency and with 
complications of therapy with vitamin K antagonists. FDA 
approval of Ceprotin ® for severe congenital PC deficiency 
was obtained in 2007 (orphan drug status). The French human 
plasma-derived concentrate Protexel® (LFB, France) has been 
available since 1994.
Manufacturing of human protein C 
concentrates
As mentioned, two human PC concentrates are available for 
the treatment of severe congenital PC deficiency in Europe 
and North America: the human plasma preparation Ceprotin® 
(Baxter) and the French PC concentrate Protexel® (LFB, 
Les Ulis, France). Another, hence-activated human PC con-
centrate, Anact® (Kaketsuken, Kumamoto, Japan), is only 
available in Japan.
Ceprotin® is a sterile lyophilized human PC concen-
trate produced from frozen human plasma, collected 
in the United States or Europe. The cryoprecipitate is 
separated and the prothrombin-complex is isolated by 
DEAE-Sephadex, leading to a fraction of plasma, rich 
in factor VII, factor IX, protein S and PC. The product 
undergoes several washing steps using anion exchange 
chromatography and immunoaffinity chromatography 
on a murine monoclonal antibody against human PC. 
Two virus inactivation steps are performed by polysorbat 
80 treatments and vapor heating (60°C for 10 hours and 
80°C for 1 hour). Human albumin is added as a stabilizer 
before sterile filtration. The concentrate is negatively 
tested for HIV, hepatitis A, B, C and parvovirus B19. Acti-
vated PC and murine IgG are not detectable. Ceprotin® 
contains heparin and, potentially, mouse protein. The 
content of more than 200 mg sodium in daily maximum 
dosing has to be taken into account in patients with renal 
insufficiency. Both human PC concentrates contain the 
inactive PC zymogen, which is activated after infusion 
and allows controlling of PF and DIC in PC-deficient 
patients. The Ceprotin® solution has a specific PC activity 
of more than 200 IU/mg protein and can be administered 
directly as intravenous infusion. The administration of 
1 IU human PC concentrate Ceprotin® leads to a median 
increase of plasma PC activity of 1.4%. Half-life is indi-
vidually variable between 4.4 and 15.9 hours (median 10 
to 12 hours). During acute PF or DIC, half-life can vary 
significantly due to ongoing consumption. Individual 
recovery also shows a wide range of 20.4% to 83.2% 
(median 68.5%).36
Protexel® is produced from human plasma donations by 
cryoprecipitation and undergoes three anion exchange chro-
matography and affinity chromatography purification steps. 
Virus inactivation steps are performed with 1% polysorbat 80 
and 0.3% tri(n-butyl)phosphate, which effectively inactivates 
enveloped viruses. Protexel® yields a specific PC activity of 
more than 100 IU/mg total protein. Half-life ranges from 
7.8 to 11 hours in adults in a stable situation, dependent on 
the acuity of the disease. Recovery is 1.58% (range 0.8 to 
1.91%) per IU/kg injected.
Anact® is produced from human plasma collected from 
unpaid donors in Japan and activated by human thrombin, 
followed by further washing steps with ion exchange chro-
matography and monoclonal antibody separation as described 
by Katsuura.37 Virus inactivation is performed by dry heat at 
65°C for 10 hours and 15 nm nanofiltration. This concentrate 
is only available in Japan. Since there are only two case 
reports on the use of this activated human PC concentrate in 
the English literature, this concentrate will not be discussed 
further.38–39
Clinical use of human protein C 
concentrates
Reported cases on the clinical use of PC concentrates in 
patients with severe congenital PC deficiency are summa-
rized in Table 1. Human PC concentrates have been suc-
cessfully used for the treatment of acute PF, DIC, DVT, and 
coumarin-induced skin necrosis, as well as for prophylaxis 
to avoid relapse of acute symptoms, in the initial phase of 
OAC therapy, and during surgical procedures.
Use in acute clinical situations
Reports of 62 patients treated with human PC concentrate 
are available (Table 1). Forty patients were treated for 
typical neonatal manifestation, specifically PF in 36 of 
them. Intracerebral hemorrhage or infarction was present 
in 13 patients and eye complications, ie, vitreous hemor-
rhage and retinal arterial thrombosis and hemorrhage 
were present in 26 patients. Seven patients presented 
with coumarin-induced episodes of skin necrosis, three 
of them were adult patients, and four were children aged 
8 to 16 years. Two patients were treated because of DVT. 
Only patients reported by Dreyfus et al23 were treated 
with Protexel®, all other patients received Ceprotin® or 
the corresponding former PC concentrate, developed by 
Immuno AG, Vienna.14,17–21,33,35,40–68
In the vast majority of cases, treatment was initiated 
by replacement of FFP at doses of 10 to 15 mL/kg every Biologics: Targets & Therapy 2010:4 54
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6 to 12 hours (next to heparin, cryoprecipitate, tissue plas-
minogen activator and others), followed by substitution of 
human PC concentrate, as soon as diagnosis of severe PC 
deficiency was made and/or the product was available. To 
treat PF or DIC, the daily dose of human PC concentrate 
varied between 80 IU/kg in a single daily dose and 750 IU/
kg in repeated doses (250 IU/kg every 6 hours) depending 
on the degree and resolution of clinical symptoms during 
treatment. In most cases the dosage of PC concentrate was 
titrated according to target PC activity levels of 100% and 
trough levels of 25%, or was adapted according to clinical 
stabilization, usually occurring after several days to weeks. 
Recurrent episodes of PF during OAC with vitamin K 
antagonists were treated with PC concentrate. Dosage of PC 
concentrate in these occasions ranged from 80 IU/kg once 
daily to 100–125 IU/kg as a first dose followed by repeated 
doses of 75 IU/kg to 200 IU/kg every 6 hours until resolution 
of lesions. Doses of PC concentrate in patients with DVT 
ranged from 40 IU/kg every 6 to 18 hours to 100 IU/kg once 
a day for 2 weeks. Patients with coumarin-induced skin 
necrosis were successfully treated with PC concentrate at 
doses of 80 IU/kg per day for several days and overlapping 
to the initiation of OAC.18,20–21,44,68,69
In general, patients with acute PF and/or DIC receiving 
PC concentrates in the early stage of the disease showed a 
much more favorable outcome than patients receiving PC 
concentrates after several days. However, early administration 
of PC concentrates in patients with intrauterine, intracerebral, 
or intraocular hemorrhage or infarction did not prevent long-
term neurological complications or visual impairment. Few 
cases are reported where treatment with FFP or PC concen-
trate was too late to save the patient’s life.23,41,52,54,56,63–64
General recommendations
No well-defined general dose guidelines are available for the 
treatment of symptomatic patients with severe congenital PC 
deficiency. However, available information from small case 
series and case reports suggests that the use of FFP or PC 
concentrates may positively influence long-term outcomes, 
especially when administered early in the disease. Based on 
this information, several recommendations have been pub-
lished recently. The American College of Chest Physicians 
(ACCP) guidelines for antithrombotic therapy in symptom-
atic neonates and children recommend treatment with either 
10 to 20 mL/kg FFP every 12 hours or PC concentrates at 20 
to 60 IU/kg until resolution of clinical lesions.70 Goldenberg 
and Manco-Johnson recommend a higher and more frequent 
dosage of PC concentrates consisting of an initial bolus of 
100 U/kg followed by 50 U/kg every 6 hours or administra-
tion of 10 to15 mL/kg of FFP every 8 to12 hours until PC 
concentrate is made available.71 Knoebl et al suggest the 
administration of PC concentrate as an initial intravenous 
dose of 60 to 80 U/kg followed by injections every 6 hours, 
especially during the acute phase.36 Further dosage should 
be planned on an individual basis aiming at a PC activity of 
100% (=100 U/dL) or a trough level of about 50 U/dL. The 
measurement of plasma PC activity before and after injec-
tion of PC is recommended in order to assess recovery and 
half-life, as both may be significantly reduced due to acute 
thrombotic events. Continuous infusions of PC concentrate 
seem to be efficient without loss of activity of PC. White 
et al recommend administration of a testing dose of 10 
IU/kg of PC concentrate, followed by a bolus dose of 100 
IU/kg, and a continuous infusion of 10 U/kg/h, adjusted to 
the measured PC activity and recovery.72 Alternatively, sub-
cutaneous administration of PC concentrate has also been 
described, especially for long-term treatment. In patients 
with coumarin-induced skin necrosis, the administration of 
heparin in therapeutic doses concomitant with intravenous 
PC concentrates is recommended.71
Prophylactic use
The goal of prophylactic administration of PC concentrates 
in patients with severe PC deficiency is to prevent relapse 
of acute disease, clinical manifestation during surgical 
procedures or pregnancy, and in the initial phase of OAC 
therapy.14,18,20,23,33,40–42,44–47,49–52,56–58,60–63,68,75
Prophylactic treatment is initiated after stabilization 
of clinical symptoms to allow an outpatient management 
(Table 1). In the patients reported, PC concentrate was indi-
vidually reduced in dose and frequency from the therapeutic 
to a prophylactic level. Dose regimens of 24 to 90 IU/kg once 
a day, 250 to 350 IU/kg every other day, or 90 IU/kg three 
times a week were reported. Trough levels of PC above 15 
to 25% as well as PC plasma level of 40 to 50% are thought 
to be sufficient to prevent relapse of PF or breakthrough skin 
necrosis. As an alternative to the intravenous route, several 
cases of subcutaneous administration of PC concentrate have 
been reported.40,45–46,56,61 Subcutaneous doses of PC concen-
trate range between 66 to100 IU/kg once a day, 350 IU/kg 
every other day, and 250 IU/kg every third day. Duration of 
subcutaneous PC concentrate administration varies between 
1 to 48 hours. For continuous subcutaneous PC infusion by 
pump, doses ranging from 192 to 350 IU/kg/48 hours are 
reported. Half-life of PC following intravenous and sub-
cutaneous administration is 6 and 16 hours, respectively.57 Biologics: Targets & Therapy 2010:4 58
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